Remodulin Granted Patent-Term Extension

The U.S. Patent and Trademark Office has granted a five-year patent-term extension to United Therapeutics for its pulmonary hypertension drug Remodulin.

The patent's original expiration date was scheduled for Oct. 6, 2009. Under the new extension, however, the patent will now expire Oct. 6, 2014.